Skip to content

Clinical, Inflammatory and Functional Evaluation of a Population of Severe and Obese Asthmatics: Follow up

Brazilian Severe Asthma Cohort Follow up: Clinical, Inflammatory and Functional Evaluation of a Population of Severe Asthmatics Based in Possible Phenotypes and Pathophysiologic Study of Obesity Association

Status
UNKNOWN
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT03532685
Acronym
BRASAFUSP
Enrollment
110
Registered
2018-05-22
Start date
2018-05-31
Completion date
2019-02-28
Last updated
2018-05-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Obesity, Severe Asthma

Keywords

Asthma, severity, follow up, obesity, bariatric surgery

Brief summary

In the study of a population of severe asthmatics, not controlled despite the treatment conducted, it was possible to evidence 5 phenotypic groups of patients. According to the refractoriness of the response to treatment, severe asthma may be phenotype in some distinct groups.Other prospective study found a large proportion of severe asthmatics with persistent airway obstruction, despite optimized treatment and systematic follow-up. Small airway involvement and remodelling, characterized by bronchial muscle thickening, appear to be the main culprits for asthma severity and persistent obstruction in this population.A point of interest in the severe asthmatics cohort was the vast majority were female and there were a considerable number of obese. Recent reviews show that the more consistent division of phenotypes in patients with severe asthma is still based on 3 previously described criteria (presence of atopy, eosinophilia and age of onset of asthma) and a more recent criterion for the presence of multi-comorbidities. Heterogeneity is the rule, the presumption of a natural evolution of gravity is not confirmed and the overlap of clusters is frequent. The stability and natural history of the phenotypes is poorly understood, postulating that the inflammatory activation of the severe asma is multifactorial and may resemble that described in the oncology literature.To date, there are no markers that allow prediction of lung evolution of most patients with severe asthma, and which patients are at greater risk of developing persistent or accelerated loss airflow or lung function, factors determining the severity of asthma. It is also unclear whether and how much phenotype-based treatment impact on disease control and prognosis. Future studies will be instrumental in defining how and why. These phenotypes are evolving, leading to the disabling characteristics of severe asthma and what may be the more effective therapeutic approaches for these patients. Since the initiated research group from 2006 has an extensive clinical, functional, inflammatory, tomographic and morphological evaluation of a cohort of patients with severe asthma, the ideal scenario exists to advance the understanding and investigation of the evolution of this rare disease through standardized follow-up.

Interventions

PROCEDUREBariatric

withdrawing a part of the stomach and may or may not be combined with bowel deviation

Sponsors

AstraZeneca
CollaboratorINDUSTRY
University of Sao Paulo General Hospital
Lead SponsorOTHER

Study design

Allocation
NON_RANDOMIZED
Intervention model
SEQUENTIAL
Primary purpose
SUPPORTIVE_CARE
Masking
NONE

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* Moderate to severe asthma (GINA step 3-5), followed in the outpatient clinic * Non-smokers, smokers or former smokers of ≤ 10 packets per year. For smokers, \<10 cigarettes / day and with onset asthma before onset of smoking * Obese asthma patients BMI\>30 kg / m2 FEV1 pre bronchodilator between 50 and 80% predicted * Normal Chest Xray

Exclusion criteria

* Pregnancy * Patients with a history of neoplasia, HIV + or other comorbidities that may interfere in the the study * Patients with no understanding of the study procedures or who are not able to give their free and informed consent; * Patients with other lung diseases such as chronic obstructive pulmonary disease, bronchiectasis, cystic fibrosis, or other lung diseases that may interfere with the study evaluation; * Non adherence to standard asthma treatment; * Inability to perform lung function assessment tests; * Pulmonary exacerbation up to 30 days before the first study evaluation

Design outcomes

Primary

MeasureTime frameDescription
Forced Expiratory Volume first second (FEV1) - Unit: litersup to 10 yearsTo assess the rate of loss of lung function in patients with severe asthma, who remain in regular follow - up and under adequate therapy since 2006.
Impulse oscillometry: combined resistance and reactance measures (R5, R20, R5-20) kilopascal - unit: Liters -1/second -16-8 monthsTo evaluate the functional airways characteristics of obese asthmatic patients, compared to non-obese asthmatics, before and after bariatric surgery

Secondary

MeasureTime frameDescription
Morbimortality - unit: number patients/yearup to 10 yearsMortality and Hospitalizations per patient/year
Residual Volume (RV) - Litersuo to 10 yearsTo compare the degree of air trapping
Asthma exacerbations - unit: exacerbation/patient/year (number)up to 10 yearsRate of exacerbations per patient/year
Ratio Residual Volume/Total Lung Capacity - Percentual (%)up to 10 yearsTo compare the degree of air trapping
Nitrogen Washout Test - Percentual (%)up to 10 yearsTo compare the heterogeneity amount of small airways
Total Lung Capacity (TLC) - Litersup to 10 yearsTo compare the degree of air tapping
Bronchial thickening measures overtime - unit: Percentage (%) bronchial wall areaup to 10 yearsTo compare the degree of bronchial thickening, through chest tomography

Contacts

Primary ContactRafael Stelmach, MD/PHD
rafael.stelmach@incor.usp.br+551126615695
Backup ContactRegina Carvalho-Pinto, MD/PHD
regina.carvalho@incor.usp.br+551126615695

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026